BTMD biote Corp.
Medicinal Chemicals & Botanical Products · Nasdaq · SEC CIK 1819253 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-8.6%
TTM net income YoY-106.7%
TTM EPS YoY-108.9%
Revenue 3-yr CAGR-1.0%
Net income 3-yr CAGR—
Margins
Gross margin67.5%
Operating margin5.0%
Net margin-1.1%
FCF margin4.1%
EBITDA margin6.6%
Returns
ROE—
ROA-1.8%
ROIC (approx.)18.5%
Asset turnover1.68x
Leverage & solvency
Liabilities / assets156.6%
Debt / equity—
Current ratio1.37x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-7.26x
Accruals ratio-14.9%
Payout ratio—
Capex / revenue3.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $43.33M | $44.23M | $44.94M | $46.41M | $47.96M | $48.86M | $48.99M | $49.83M |
| Cost of revenue | $14.00M | $15.31M | $13.98M | $14.84M | $13.54M | $13.88M | $12.61M | $14.30M |
| Gross profit | $29.33M | $28.92M | $30.95M | $31.57M | $34.42M | $34.99M | $36.38M | $35.53M |
| SG&A expense | $26.84M | $32.43M | $27.79M | $24.74M | $26.15M | $24.22M | $26.69M | $32.76M |
| Operating income | $2.49M | -$3.51M | $3.17M | $6.83M | $8.27M | $10.77M | $9.69M | $2.77M |
| Pretax income | $1.36M | -$7.13M | $3.34M | $5.60M | $8.45M | $6.08M | $17.45M | -$1.22M |
| Income tax | $796,000 | $296,000 | $662,000 | $2.99M | -$765,000 | $2.15M | $1.62M | -$4.70M |
| Net income | $407,000 | -$6.56M | $2.28M | $1.95M | $8.19M | $3.19M | $13.72M | $3.70M |
| EBITDA | $2.96M | -$3.10M | $4.15M | $7.78M | $8.63M | $11.04M | $10.55M | $3.90M |
| EPS (basic) | 0.01 | -0.23 | 0.07 | — | 0.26 | 0.10 | 0.44 | — |
| EPS (diluted) | 0.01 | -0.23 | 0.06 | — | 0.22 | 0.10 | 0.37 | — |
| Weighted avg. shares (diluted) | 27.42M | 28.63M | 36.00M | — | 36.71M | 31.74M | 36.95M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $8.85M | $11.17M | $5.32M | $24.12M | $28.05M | $19.60M | $41.70M | $39.34M |
| Receivables | $7.29M | $7.81M | $7.40M | $6.87M | $7.97M | $9.07M | $7.76M | $7.63M |
| Inventory | $17.77M | $18.33M | $19.88M | $19.06M | $16.45M | $12.13M | $13.45M | $14.85M |
| Current assets | $41.76M | $43.04M | $36.36M | $54.67M | $57.12M | $49.50M | $68.68M | $68.13M |
| PP&E, net | $14.96M | $12.85M | $10.70M | $10.75M | $10.06M | $9.93M | $8.39M | $6.97M |
| Goodwill | $5.83M | $5.83M | $5.83M | $5.83M | $5.83M | $5.83M | $5.83M | $5.83M |
| Intangibles | $3.34M | $3.65M | $3.96M | $4.27M | $4.57M | $4.88M | $5.19M | $5.50M |
| Total assets | $101.70M | $101.70M | $89.03M | $107.61M | $111.32M | $104.80M | $123.38M | $122.37M |
| Current liabilities | $30.50M | $30.10M | $28.23M | $44.99M | $56.31M | $50.54M | $48.47M | $51.51M |
| Short-term debt | $3.12M | $3.12M | $6.25M | $6.25M | $6.25M | $6.25M | $6.25M | $6.25M |
| Long-term debt | $116.95M | $118.38M | $94.42M | $95.78M | $97.13M | $98.49M | $99.85M | $101.20M |
| Total debt | $120.07M | $121.50M | $100.67M | $102.03M | $103.38M | $104.74M | $106.10M | $107.45M |
| Total liabilities | $159.29M | $159.89M | $136.99M | $158.01M | $176.79M | $183.64M | $208.21M | $224.57M |
| Shareholders' equity | -$65.35M | -$65.79M | -$56.09M | -$58.54M | -$72.75M | -$85.10M | -$89.98M | -$105.93M |
| Net debt | $111.22M | $110.33M | $95.36M | $77.91M | $75.33M | $85.14M | $64.40M | $68.11M |
| Cash flow statement | ||||||||
| Operating cash flow | $3.69M | -$1.18M | $3.90M | $7.57M | $14.07M | $7.09M | $6.47M | $12.37M |
| Capital expenditure | $2.58M | $2.56M | $362,000 | $1.08M | $499,000 | $1.81M | $1.63M | $1.67M |
| Free cash flow | $1.11M | -$3.73M | $3.54M | $6.49M | $13.57M | $5.28M | $4.84M | $10.70M |
| Investing cash flow | -$3.03M | -$2.62M | -$1.17M | -$2.36M | -$690,000 | -$1.96M | -$1.85M | -$1.31M |
| Financing cash flow | -$2.97M | $9.65M | -$21.54M | -$9.13M | -$4.93M | -$27.23M | -$2.26M | -$9.93M |
| Depreciation & amortization | $468,000 | $411,000 | $980,000 | $951,000 | $364,000 | $270,000 | $857,000 | $1.14M |
| Stock-based compensation | $1.34M | $1.97M | $1.76M | $2.20M | $2.41M | $2.19M | $2.13M | $1.89M |
| Dividends paid | $8,000 | $616,000 | $405,000 | $138,000 | $8,000 | $887,000 | $694,000 | $88,000 |
| Share buybacks | $1.36M | $4.79M | $1.07M | $0 | — | — | — | $0 |
Free plan shows the latest 8 periods; Pro shows all 25 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.